Covid vaccination beneficiaries below target due to vaccine hesitancy: Govt

Fewer than planned beneficiaries attended the coronavirus vaccination sessions at the start due to transient technical issues in CoWIN portal and vaccine hesitancy, among others, the government said

Beneficiary gets a Covid-19 vaccine at City Dispensary, in Bikaner
Beneficiary gets a Covid-19 vaccine at City Dispensary, in Bikaner
Press Trust of India New Delhi
2 min read Last Updated : Feb 05 2021 | 11:11 PM IST

Fewer than planned beneficiaries attended the coronavirus vaccination sessions at the start due to transient technical issues in CoWIN portal and vaccine hesitancy, among others, the government informed the Parliament on Friday.

A total of 7,580 adverse events following immunisation have been reported till January 31 under the rollout. None of the 12 deaths of vaccinated persons have been causally attributed to the vaccination as per the current evidence, Minister of State for Health Ashwini Choubey told the Lok Sabha.

Responding to a question on the urgency on part of the government to go ahead with the vaccination when the cases are declining, Choubey said a second or third peak was experienced in other countries during the later part of the pandemic.

"Therefore, a declining trend of cases in the country does not necessarily promise a continued and steady decrease in cases," he said. "Hence, it is necessary to provide prompt protection to the vulnerable and at risk population and maintain low case count through COVID-19 vaccination."

As per the fact sheet of the vaccine manufactured by Bharat Biotech, one should not get Covaxin if the person has any allergies, fever, bleeding disorder or are on blood thinner, immune-compromised individuals or on medicines that affect immune system, pregnant, breastfeeding, received another coronavirus vaccine or any serious health-related issues, Choubey said in a written reply.

As per the fact sheet of Serum Institute, one should not get Covishield if a person had a severe allergic reaction after a previous dose of this vaccine and had a severe allergic reaction to any ingredient of this vaccine, he said.

The healthcare provider needs to be consulted about medical conditions, including severe allergic reaction after any drug, food, any vaccine or any ingredients of Covishield; fever; bleeding disorder; immunocompromised; pregnant; breastfeeding or received another COVID-19 vaccine, the minister said.

Only those COVID-19 vaccines that have been granted permission for restricted use in emergency situation by the Drugs Controller General of India have been used for COVID-19 vaccination drive in the country.

As per New Drugs and Clinical Trials Rules, 2019, the Central Drugs Standard Control Organisation has granted permission to manufacture two vaccines based on the prescribed procedure and due evaluation of pre-clinical and clinical trial data.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Feb 05 2021 | 11:07 PM IST

Next Story